Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
"ASCO guideline: chemotherapy-induced peripheral neuropathy." J Clin Oncol 2020;38(28):3325-48
Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, Verhaar JA, Van Glabbeek F, Van Meurs JB, Kerkhof HJ, Hofman A, Stricker BH, Bierma-Zeinstra SM
In the SURMOUNT-1 clinical trial, patients taking the highest dose (15 mg) of tirzepatide lost about 21% of their body weight over 72 weeks
Losing weight can also contribute to weakened bones
GLP-1 SG is a research peptide commonly investigated in laboratory environments involving receptor pathway interactions and signaling studies
This randomized phase 3 clinical trial took place at 45 medical research centers and hospitals in 8 countries
